Biodexa Pharmaceuticals Plc

BST:5MPA Stock Report

Market Cap: €2.9m

Biodexa Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Biodexa Pharmaceuticals has been growing earnings at an average annual rate of 9.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 21.4% per year.

Key information

9.8%

Earnings growth rate

-14.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-21.4%
Return on equity-242.1%
Net Margin-1,095.3%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Biodexa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:5MPA Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 221-855
30 Sep 221-745
30 Jun 221-535
31 Mar 221-535
31 Dec 211-535
30 Sep 211-742
30 Jun 211-830
31 Mar 210-1540
31 Dec 200-2250
30 Jun 200-2250
31 Mar 201-1650
31 Dec 191-940
30 Jun 192-940
31 Mar 192-1040
31 Dec 182-1040
30 Jun 181-1140
31 Mar 181-1140
31 Dec 171-1240
30 Sep 17-3-1-7-5
30 Jun 174-18106
31 Mar 176-19147
31 Dec 161-630
30 Sep 165-171210
30 Jun 164-13136
31 Mar 163-1296
31 Dec 151-1039
30 Sep 151-1065
30 Jun 150-1174
31 Mar 150-1064
31 Dec 140-944
30 Sep 140-743
30 Jun 140-523
31 Mar 140-423
31 Dec 130-423

Quality Earnings: 5MPA is currently unprofitable.

Growing Profit Margin: 5MPA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 5MPA is unprofitable, but has reduced losses over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare 5MPA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5MPA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: 5MPA has a negative Return on Equity (-242.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.